Your browser is no longer supported. Please, upgrade your browser.
Settings
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E21.30 EPS (ttm)8.00 Insider Own0.10% Shs Outstand308.81M Perf Week-0.69%
Market Cap52.63B Forward P/E10.55 EPS next Y16.15 Insider Trans0.00% Shs Float303.22M Perf Month-1.48%
Income2.44B PEG4.18 EPS next Q3.67 Inst Own20.50% Short Float0.38% Perf Quarter0.48%
Sales15.53B P/S3.39 EPS this Y160.00% Inst Trans0.03% Short Ratio1.35 Perf Half Y27.12%
Book/sh120.84 P/B1.41 EPS next Y5.85% ROA7.20% Target Price201.82 Perf Year15.19%
Cash/sh0.90 P/C189.72 EPS next 5Y5.10% ROE13.50% 52W Range123.73 - 177.51 Perf YTD9.86%
Dividend1.05 P/FCF- EPS past 5Y7.50% ROI4.30% 52W High-3.99% Beta1.24
Dividend %0.62% Quick Ratio1.00 Sales past 5Y27.30% Gross Margin71.00% 52W Low37.74% ATR2.09
Employees23044 Current Ratio1.60 Sales Q/Q4.60% Oper. Margin19.90% RSI (14)50.77 Volatility1.09% 1.03%
OptionableYes Debt/Eq0.49 EPS Q/Q153.50% Profit Margin31.10% Rel Volume0.63 Prev Close171.50
ShortableYes LT Debt/Eq0.45 EarningsJul 31 BMO Payout5.50% Avg Volume849.91K Price170.42
Recom1.70 SMA20-0.77% SMA501.22% SMA20011.43% Volume532,083 Change-0.63%
May-11-18Resumed Kepler Buy
Feb-20-18Downgrade JP Morgan Overweight → Neutral
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $201 → $181
Feb-14-18Upgrade Bernstein Mkt Perform → Outperform
Dec-20-17Downgrade Liberum Buy → Hold
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Aug-17-18 02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Aug-15-18 02:00AM  Rule 2.9 Announcement GlobeNewswire
Aug-14-18 02:00AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Aug-13-18 12:36PM  Shire, Shionogi File NDA for Intuniv for Adults in Japan Zacks
10:16AM  Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold Zacks
02:00AM  New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults with ADHD GlobeNewswire
Aug-10-18 02:00AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Aug-09-18 02:00AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Aug-08-18 02:00AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Aug-07-18 06:00AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
02:00AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Aug-06-18 07:24PM  Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Aug-01-18 10:12AM  Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2 Zacks
05:01AM  Shire plc : Total voting rights GlobeNewswire
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
02:01AM  Shire plc : Half-year Report GlobeNewswire
Jul-31-18 09:57AM  Shire plc : 2nd Quarter Results GlobeNewswire
08:37AM  [$$] Takeda profits hit as cancer drug loses market protection Financial Times
08:34AM  Shire: 2Q Earnings Snapshot Associated Press
08:28AM  [$$] Shires immunology unit shines in Q2 but haemophilia sales stall Financial Times
07:49AM  Shire profit edges higher ahead of Takeda sale Reuters
Jul-30-18 02:01AM  Shire plc : Miscellaneous GlobeNewswire
Jul-26-18 02:05AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-25-18 10:36AM  Shire plc : Director Declaration GlobeNewswire
02:07AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-24-18 01:25PM  NYSE trader: Amazon, Visa and Twitter earnings are on my radartheir charts are very similar Yahoo Finance Video
11:01AM  Shire plc : Director Declaration GlobeNewswire
Jul-23-18 07:05AM  Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks ACCESSWIRE
02:01AM  Shire plc : Notice of Results GlobeNewswire
Jul-20-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-19-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-17-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-12-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-11-18 10:04AM  Company News For Jul 11, 2018 Zacks
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-10-18 10:58AM  U.S. regulator backs Takeda's $62B acquisition of Shire American City Business Journals
05:33AM  Japan's Takeda gains U.S. approval for $62 billion Shire buy Reuters
03:47AM  Takeda gets key U.S. regulatory approval to buy Shire Reuters
03:19AM  Takeda Clears Hurdle for $62 Billion Shire Deal Bloomberg
02:01AM  Shire plc : Rule 2.9 announcement GlobeNewswire
Jul-09-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-05-18 09:35AM  Is Shire (SHPG) a Great Stock for Value Investors? Zacks
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-04-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-03-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jul-02-18 08:01AM  Shire plc : Total voting rights GlobeNewswire
02:02AM  Shire plc: Director/PDMR Shareholding GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Susan Kilsby GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Steven Gillis GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Sara Mathew GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Olivier Bohuon GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Ian Clark GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Gail Fosler GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - David Ginsburg GlobeNewswire
02:01AM  Shire plc : Form 8 (DD) - Albert Stroucken GlobeNewswire
02:01AM  Shire plc : CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI(R) FOR ADULTS WITH VON WILLEBRAND DISEASE GlobeNewswire
Jul-01-18 10:00PM  New Takeda HQ Flaunts Global Ambition Alongside Japan Roots Bloomberg
Jun-29-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-28-18 05:13AM  Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour Reuters
05:11AM  Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor Reuters
02:01AM  Shire plc : Rule 2.9 announcement GlobeNewswire
Jun-27-18 02:01AM  Shire plc : Rule 2.9 announcement GlobeNewswire
Jun-26-18 10:14PM  [$$] Takeda chief seeks to allay £46bn Shire bid concerns Financial Times
02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-22-18 10:14AM  FDA approves $1.2B plasma manufacturing center near Covington American City Business Journals
09:56AM  Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population Zacks
05:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
02:01AM  Shire plc: Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas GlobeNewswire
Jun-21-18 02:03PM  Nike takes a dive, Spotify surges, Shire up slightly Yahoo Finance
12:03PM  Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia GlobeNewswire
10:43AM  Nike, Spotify and Shire are the Yahoo Finance charts of the day. Yahoo Finance Video
02:01AM  Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE GlobeNewswire
Jun-20-18 07:50AM  Stock Performance Review on Sesen Bio and Three Other Biotech ACCESSWIRE
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-19-18 02:01AM  Shire plc: Rule 2.9 Announcement GlobeNewswire
Jun-18-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-15-18 09:13AM  5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-14-18 12:05PM  3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry InvestorPlace
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-13-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-12-18 07:01AM  How Takeda CEO Sells Japan's Biggest Deal to Doubters Bloomberg
04:45AM  Takeda and Shire Have a $60 Billion Drug Problem Bloomberg
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-11-18 09:04AM  Takeda shareholder group aims to block $62 billion Shire deal Reuters
08:05AM  Takeda shareholder group aims to block $62 billion Shire deal Reuters
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-08-18 02:02AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-07-18 02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-06-18 05:56PM  'Right to Try' Law Says Yes, the Drug Company Says No The Wall Street Journal
08:07AM  Shire launches screen responsibly, an eyelove® initiative dedicated to prioritizing eye health in a screen-saturated world PR Newswire
02:02AM  Shire plc : Rule 2.9 announcement GlobeNewswire
Jun-05-18 08:20AM  New Research: Key Drivers of Growth for Helen of Troy, Macro Bank, American Software, Shire plc, KB Financial Group, and Odonate Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
03:42AM  [$$] Takeda shareholders band together against £46bn Shire deal Financial Times
Jun-04-18 10:01AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Jun-01-18 10:34AM  What Does Shire plcs (LON:SHP) Ownership Structure Look Like? Simply Wall St.
07:01AM  Shire plc : Total voting rights GlobeNewswire
02:01AM  Shire plc : Rule 2.9 Announcement GlobeNewswire
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.